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INTRODUCTION 
Omega-3 family is polyunsaturated fatty acids that the 
first double bond is located between the third and fourth 
carbon in the carbon chain. Omega-3 fatty acids are 
essential ingredients for regulating the activity of the 
human body, but don’t produce in the body. Essential 
fatty acids prevents from deposition and accumulation of 
cholesterol in the arteries and the progression of 
atherosclerosis.
1
  
Several studies have shown that omega-3 fatty acids by 
reducing the gene expression of strolls regulatory element 
binding proteins (SREBPs) include SREBP-1C, SREBP-
1a, and SREBP-2. They also increase the destruction of 
these proteins in Proteasom that reduce their 
concentration in the liver cells and thus reduce the gene 
expression of enzymes effective on fatty biosynthesis in 
the liver. Reduction of fatty acids synthesis in the liver 
caused to decrease of the synthesis of triglycerides (TG) 
and very low density lipoproteins (VLDL) in the liver. 
Therefore, entrance of the VLDL to blood is decreased 
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and triglycerides concentration in the blood is also 
declined.
2-5
  
The basic precursor material for omega-3 is α-linolenic 
acid (α-ALA) that mainly achieved from vegetable grain's 
oil. In recent years, new compounds have been marketed 
as supplements of omega-3 that unlike to conventional 
omega-3 compounds with 300 mg EPA and 400 mg DHA 
containing 900 mg DHA and 800 mg EPA. These 
compounds offered with the names of Omacor capsules 
or Omega MAX. Higher amount of EPA and DHA of 
Omega MAX and its use once a day, instead of 3 times a 
day for conventional omega-3 capsules, resulted to high 
tendency for this capsule.
6
  
Epidemiological studies showed a direct correlation 
between high intake of saturated fatty acids 
Hypolipidemy and death from cardiovascular diseases. 
These studies proved that increase of dietary unsaturated 
fatty acids (especially omega-3) has higher beneficial 
effect on cardio-vascular disease compared to reducing 
the amount of saturated fatty acids.
7
 Although, reduction 
of serum low density lipoproteins (LDL) is the first 
immune response to reduce the diseases associated with 
atherosclerosis, but increase of serum triglycerides 
decreases high density lipoproteins (HDL) and produces 
the higher amount of small and more concentrated LDL 
particles. These changes increase the risk of coronary 
heart disease.
8-10
  
TG to HDL ratio is superior in predicting myocardial 
infarction and arterial thrombosis than LDL to HDL ratio. 
Atherosclerosis and cardio-vascular disease are from the 
main causes of mortality in chronic kidney disease 
undergoing hemodialysis. Therefore, use of therapeutic 
procedures to cure these disorders is valuable. In order to 
prevent the occurrence of atherosclerosis caused by 
hemodialysis, prescription of blood lipid-lowering drugs 
and anti-oxidants is inevitable, but studies emphasized on 
the treatment methods that are effective in reducing the 
independent risk factors of atherosclerosis such as 
Lipoprotein-a.
11,12
  
Chronic kidney disease (CKD) includes a range of 
different pathophysiologic processes that associated with 
abnormal renal function and progressive decline in 
glomerular filtration rate. Cardiovascular disease is the 
main cause of mortality in patients at any stage of CKD 
that related to hyperphosphatemia, and other risk factors 
like hypertension, hypervolemia, dyslipidemia, increased 
sympathetic activity and hyperhomo-cysteinemia.
13
  
Chronic renal failure produces from progressive and 
irreversible degradation of nephrons and its treatment in 
the later stages carried out by hemodialysis or peritoneal 
dialysis and kidney transplant.
14,15
 Free radicals effect on 
lipids, proteins and carbohydrates. Lipids have the 
greatest sensitivity for free radicals.
16
 some studies 
suggested that the process of dialysis increases free 
radical production. Increased production of free radicals 
during hemodialysis in dialysis apparatus is probably due 
to direct contact of dialysis apparatus with patient's blood 
in normal oxygen pressure that creates oxidative 
stress.
16,17
 In hemodialysis patients, high levels of 
systemic inflammatory parameters (C-reactive protein) is 
one of the major risk factors for cardiovascular disease.
8,9
 
Several studies showed the relation between increased 
plasma concentrations of Lp (a) with atherosclerosis and 
coronary arteries diseases caused by it, in particular in 
hemodialysis patients. Most of researchers declared that 
Lp (a) act as a risk factor for heart disease. Therefore, 
finding a pharmacological agents that have the ability to 
lower these risk factors will have great therapeutic 
value.
10,18
 In a study carried out in the Department of 
Nephrology, Hospital, Aalborg, Denmark of the 
hemodialysis patients were fed with high doses of fish oil 
containing a large amounts of omega-3, a significant 
decrease in triglycerides in these patients was observed 
which resulted in a significant reduction of 
cardiovascular disease risk.
19
  
Kooshki et al showed that omega-3 reduced the 
concentration of artery inflammation index that cause to 
reduce cardiac events in hemodialysis patients.
20
 The 
Taliban and colleagues study indicated the positive 
effects supplementary fatty acids in reducing the 
concentration of serum triglyceride in patients 
undergoing hemodialysis, but had no effect on the 
concentration of other serum lipids and lipoproteins in 
hemodialysis patients.
21
 Rafraf et al concluded that 
omega-3 fatty acids caused a significant decrease in LDL 
and triglycerides levels and significant increase in levels 
of serum HDL.
22
 This study aimed to determine the 
effects of omega-3 fatty acids on serum lipid levels in 
patients under treatment with chronic hemodialysis. 
METHODS 
This study was a clinical trial. The study population had 
chronic hemodialysis patients who were undergoing 
dialysis in hemodialysis center of Booali hospital in 
Ardabil city from date 21
st
 January 2015 to 21
st
 June 
2015. Study intervention carried out on 60 dialysis 
patients in dialysis section of Booali. The study groups 
included of 30 patients in treatment group and 30 patients 
in placebo group. The study conducted as a double-blind 
method. Patients were selected randomly and placed on 
study groups. The groups were dialyzed in different days 
(Omega group in even days and placebo group in odd 
days) and different place. Therefore the participants of 
two groups hadn't awareness from medication of each 
other. At the start of study the participant were under 
dialysis at least for 3 months and did not used any omega 
3 supplements, E and C vitamins, and other effective 
drugs on serum lipoproteins. Serum levels of C-reactive 
protein (CRP), TG, HDL and LDL were measured in the 
laboratory of Booali hospital. TG kit was used to measure 
triglycerides. Diagnostic kits of HDL-C and LDL-C were 
used to quantitative measure of HDL and LDL in serum 
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or plasma by photometric method. CRP calibrator and 
control serum was used to measure of CRP.  
Study design 
For patients in group 1 to 3 months a number of Omega-
MAX Omega-3 capsules after midday meal was 
prescribed. Omega-3 capsules for patients in Group 2 
also were used as a placebo and serum levels of CRP, 
TG, HDL and LDL were assessed.  
It should be noted that in this study, determination of the 
adequacy of dialysis for each patient is based on the kt/v 
index and the use of BUN concentration, duration of 
hemodialysis and the rate of ultra-filtration of fluids from 
the body, which is derived from the information in each 
patient's case. Also it should be noted that during the 
study, 3 patients were excluded from the study for 
reasons such as referral for kidney transplantation and 
accidental death, and a total of 29 patients in the drug 
group and 28 subjects in the placebo group were studied. 
Tools and methods for collecting information 
After selecting the samples, the laboratory of Booali 
Hospital of Ardabil was used for the necessary 
preliminary tests (prior to omega) and the second (after 3 
months after omega administration). For all patients, the 
forms were completed in both groups, including personal 
details, address, the cause of kidney disease, 
accompanying illnesses, and information on the adequacy 
of dialysis index and the section on the results of the 
tests. Data was entered into SPSS software version 16 
after encoding of checklists and analyzed using 
descriptive statistics and analytical statistics methods 
using paired t-test. Significant levels were considered less 
than 0.05. 
All information about the patient's case file was 
confidential and was not mentioned in the nominal study 
of patients. Before the beginning of the study, patients 
were given a detailed explanation for the study and 
prescription drug, and informed consent was obtained 
from all patients. The study approval in the Ethics 
Committee with code 93.48ARUMS. REC then recorded 
and done. The code for the clinical trial is 
1N2014112520087IRCT. 
RESULTS 
In the present study in omega 3 groups, the mean of TG, 
HDL, LDL, and CRP was not statistically significant 
before and after the intervention by using The T-test. In 
the placebo group, the mean of TG, LDL, and CRP 
before the intervention, That is, before taking omega-3 
placebo capsules, and after the administration of placebo, 
according to T-test, was not significant. While the mean 
HDL in the placebo group before intervention was 40.6 
mmol/l, after the intervention, it reached 44.5 mmol/l, 
indicating an increase in HDL. T-test showed a 
significant increase (p=0.02) (Table 1 and 2). 
Table 1: Descriptive indexes of TG, HDL, and LDL 
variables in the drug group. 
Variables 
)mmol/l( 
Before 
(mean±SD) 
After 
(mean±SD) 
P 
value 
TG 217.96±125.27 194.93±115.03 0.096 
HDL 33.93±7.24 37.25±11.69 0.061 
LDL 98.31±34.09 103.20±36.33 0.402 
Table 2: Descriptive indexes of TG, HDL, and LDL 
variables in placebo group. 
Variables 
)mmol/l( 
Before 
(mean±SD) 
After 
(mean±SD) 
P 
value 
TG 260.96±171.52 234.32±117.42 0.192 
HDL 40.60±9.60 44.50±11.41 0.020 
LDL 104.17±25.97 104.89±31.30 0.854 
According to the outcomes of this study, it can be 
concluded that in the omega-3 group, the mean TG was 
significantly reduced after medication (mean difference 
of 23.03), but due to the scattering of data concerning 
triglyceride, this reduction was not significant. 
In the placebo group, however, there was a significant 
decrease in TG, although it’s mean after placebo was 
significantly reduced (mean 24.26), but this was not 
significant, so it can be concluded that none of them the 
two groups did not show significant reductions in TG. 
Regarding HDL in omega group, the mean of that after 
omega consumption was increased compared to before 
omega consumption (mean difference of 3.32) and 
although p=0.061 was not considered meaningful, but It 
can be said that omega consumption has been effective in 
increasing HDL. 
Concerning HDL in the placebo group, with a mean 
difference of 3.89 and a significant increase in HDL after 
placebo, it can be concluded that the reason for the 
increase in HDL in this group was not related to the level 
of omega-3 fatty acids and probably have been resulted 
of factors like nutrition and etc. 
In the case of LDL, in the omega group, considering that 
the mean LDL after omega consumption was slightly 
increased compared to the mean before omega 
consumption (mean difference of -89.8), due to the lack 
of significance of these results and the changes to a very 
small extent, we conclude that omega has not been shown 
to increase LDL. Of course, in the placebo group, LDL 
changes were not significant at a mean of -0.71. 
In the case of the CRP in the omega group, with regard to 
its increase after omega consumption (mean difference of 
2.5), and its non-meaningfulness, it can be said that this 
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increase does not correlate with omega consumption and 
it can be related to the inflammatory nature of chronic 
kidney disease and other illnesses associated with the 
disorder that is common in these patients, such as 
diabetes and the like. In the placebo group, the increase in 
CRP after the use of placebo with an average of -1.257 
was also confirmed by the inflammatory nature of 
chronic kidney disease. 
Tables for statistical analysis of data are presented in two 
groups of drugs (omega) and placebo. The presented 
tables also include mean, standard deviation and p value 
variables before and after drug and placebo imposition 
(Table 3). 
Table 3: Compares the changes before and after the 
indices between the two groups of drugs and placebo. 
Variable 
(mmol/l) 
Drug 
mean 
P 
value 
Placebo 
mean 
P 
value 
TG 23.03 0.096 26.64 0.192 
HDL 3.32 0.061 -3.89 0.020 
LDL -4.89 0.402 -0.71 0.854 
CRP (mg/dl) -5.20 0.072 -1.27 0.582 
DISCUSSION 
Chronic renal failure is one of the most common kidney 
diseases, which, due to sever and irreparable 
complications, require special care and observation 
patients. Patients with end stage renal disease require 
dialysis or kidney transplantation to survive. These 
patients are prone to cardiovascular disease due to the 
nature of the end stage kidney disease and also due to the 
common diseases associated with them, including 
diabetes and the like. One of the known causes of 
cardiovascular disease in these patients is lipid 
abnormalities, the most important of which are 
triglyceride, HDL and LDL disorders. This study was 
conducted to evaluate the effects of omega-3 fatty acid 
supplementation on lipid profiles and systemic 
inflammatory markers in patients undergoing 
hemodialysis.
23
 Several studies have been done to 
evaluate the effects of fatty acid supplements on lipid 
profiles of normal people and patients from different 
groups, some of them on hemodialysis patients.
19
 For 
example, in a study done by Kooshki and et al in the title 
of the effect of supplementing omega-3 fatty acids on the 
concentration of lipids and serum lipoproteins, it was 
concluded that receiving omega-3 supplementation did 
not result in any decrease in lysophosphatidic acid (LPA) 
concentration, However, after 10 weeks of treatment, 
serum triglyceride levels were decreased compared to 
placebo group. In this study, the mean concentration of 
LPA in the omega-3 fatty acid group was 30.2±3.23 and 
in the placebo group 22±18, which was not significant 
between the two groups.
20 
Serum triglyceride concentrations in the omega group 
were 113±32.3 and in the placebo group 109±19, which 
was after the end of the study in the omega group, 
101±25 and in the placebo group, 17±115 which in the 
group receiving omega-3 fatty acid supplements By the 
end of the tenth week, the study had a significant 
reduction in the starting time of the study (p<0.01). While 
in the placebo group, it did not change over the course of 
the study. Also, serum triglyceride concentration 
reduction in the omega-3 fatty acid supplement group 
was statistically significant (p<0/004).
21
 On the other 
hand, at the onset of this study, in the omega-3 fatty acid 
group, the mean HDL-C and LDL-C concentrations were 
43±5 and 42±3.5 and in the placebo group were 10±8 and 
8±5.9, respectively. The difference there was no 
significant statistical relationship between the two 
groups. At the end of the study, the concentration of HDL 
and LDL in the fatty acids group was 42±5.4 and 41±5 
and in the placebo group, 12.5±12 and 5±3, respectively, 
which was not statistically significant. 
In the study, supplementation with omega-3 fatty acids in 
omega group did not significantly increase serum HDL-C 
concentrations compared to placebo group. In 
concurrence with the study, some studies have shown that 
omega-3 fatty acids do not increase serum HDL-C 
concentrations, but some studies have shown that omega-
3 fatty acids increase serum HDL-C concentrations. 
Contradiction in the effects of omega-3 fatty acid 
supplements on serum HDL-C concentrations is may be 
due to the difference in serum triglyceride concentration 
changes due to the use of omega-3 fatty acids, as the 
reduction in serum triglyceride concentration decreases 
the amount of triglyceride is present in serum HDL2, and 
in this case, HDL-2 lipoproteins are not suitable 
substrates for the liver lipase enzyme any more. As a 
result, converting of HDL-2 lipoproteins to HDL3 
lipoproteins those rates of catabolism is higher than that 
of HDL2 lipoproteins, decreases. Thus, decreasing 
triglyceride concentration due to supplementation of 
omega-3 fatty acids 3 can affect serum levels of HDL. In 
the study, patients with hemodialysis had a normal level 
of serum triglyceride concentrations, so that, the use of 
supplementation of omega-3 fatty acids reduced the 
serum triglyceride concentration significantly, which was 
about 12 milligrams Grams in deciliter. Therefore, 
because the reduction in serum triglyceride 
concentrations was slight in this study, the serum HDL-C 
concentration has not increased.
21
  
In another study by the Department of Nephrology, 
Aalborg Hospital, Denmark, conducted a double-blind 
study in this study, patients with hemodialysis underwent 
to high-dose fish oil supplementation that contains large 
amounts of omega-3. Finally, after statistical analysis 
found a significant reduction in the Triglyceride level but 
no other lipid profiles were altered.
22
  
Another study by Hamilton and colleagues concluded 
that omega-3 has an effect on the balance of serum lipids, 
leading to improved cardiovascular complications. In this 
study, the patients were divided into two groups, one 
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group of fish oil containing omega-3, and another group 
of olive oil, which had much lower omega-3 content. The 
mean of TG in the omega-3 group before the intervention 
was 3.3±0.3 which was 2.7±0.5 after intervention. The 
mean HDL before the intervention was 0.96±0.04 and 
after intervention 0.91±0.05. The mean of TG in the olive 
oil group before the intervention was 3.3±0.3 and after 
intervention 3.4±0.6 and the mean of HDL in the olive oil 
group before the intervention was 96.9±0.04 and after 
intervention, 0.08±0.03. Finally, it was concluded that 
although TG reduction was significant in patients 
receiving Omega-3, the increase in HDL was not 
significant. But the same reduction in TG has had a 
significant impact on the risk of cardiovascular 
morbidity.
24
  
In the present study, we have tried to prove that omega-3 
fatty acids improve lipid profiles by decreasing TG and 
LDL and increasing HDL. Meanwhile, we examine the 
effect of omega-3 fatty acids on the reduction of systemic 
inflammatory markers such (CRP). 
In the present study, although the use of omega-3 in the 
treatment group resulted in a non-significant decrease in 
triglyceride levels, this could be due to reasons such as a 
small number of samples and the dispersion of the initial 
data, and it certainly doesn’t mean non-acceptance of The 
results of previous studies have shown that omega-3 fatty 
acids have not significantly decreased TG. Additionally, 
in this study, HDL in the placebo group, in contrast to the 
treatment group, has made significant changes, which can 
be noted: The lack of significant increase in HDL in the 
omega group may be due to the lack of significant 
reductions in TG in this group, since, as in other studies, 
the positive effects of omega fats on HDL elevation on 
condition of TG reduction are also possible in this study. 
According to the results of changes in LDL and CRP in 
this study and other similar studies, it can be concluded 
that in general, omega supplements have no effect on 
LDL and inflammatory systemic index. 
Low number of patients, lack of attention to the TG of the 
patients in the two groups before the intervention, which 
leads to a large dispersion of data and the impossibility of 
nutritional measures (including regular consumption of 
fish and foods containing omega-fatty acids) were the 
limitations of the present study. 
Considering that the effect of omega-3 fatty acids on the 
increase of HDL and TG and LDL reduction in this 
study, has not been meaningful, so it is scientifically not 
possible to categorically recommend this drug for all 
patients with hemodialysis. However, according to 
previous studies, the use of these supplements in 
hemodialysis patients, even if there is no significant 
reduction in lipid profiles, will not be detrimental. In 
order to achieve definitive results, it is better to select 
larger number of patients as sample and with 
consideration of factors such as the effects of a specific 
diet of each patient and the level of baseline serum lipids 
will be resumed at other times. 
Finally, although there were no significant differences in 
lipid profile in hemodialysis patients, many patients in 
the omega-3 group showed a significant reduction in 
musculoskeletal pain, which is a common complaint in 
chronic hemodialysis patients. They expressed 
satisfaction that this could be more accurately and 
comprehensively studied in other near-term interventions 
with omega-fatty acid supplements.  
CONCLUSION  
This study concluded that omega consumption did not 
have a significant effect on reducing serum lipids (TG 
and LDL) and increase in lipid (HDL) and systemic 
inflammatory index (CRP) (p>0.05). 
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